ARTICLE

Volume 10,Issue 7

All Issues
Submit to JCNR
Cite this article
1
Citations
2
Views
7 January 2025
Current Status of Home Management of Oral Targeted Drugs for Cancer Patients
Shuangran Wang ,  Yan She ,  Xiaobo Liu ,  Jin Hang ,  Chunfeng Ruan ,  Xiaoxia Qiu
Show Less
1 Shanghai Jiguang Polytechnic College, Shanghai 200433, China,
2 Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200120, China,
JCNR 2024 , 8(12), 141–146; https://doi.org/10.26689/jcnr.v8i12.9301
© 2024 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
Cite
XML
HTML
Abstract

Malignant tumors have a high incidence in clinical practice, posing a significant threat to human health and severely impacting patients’ quality of life. Targeted drugs represent an effective therapeutic strategy, precisely addressing tumor sites to inhibit disease progression and alleviate the adverse effects of radiotherapy and chemotherapy. Despite these benefits, the use of targeted drugs often results in various adverse reactions, necessitating enhanced clinical management and protection. This study analyzes the current state of home management of oral targeted drugs in patients with malignant tumors, identifies influencing factors, and proposes improvement measures tailored to practical conditions. These efforts aim to ensure medication safety and provide valuable references for clinical practice.

References
Liu H, Li Q, Shi J, et al., 2023, A Randomized Controlled Trial of Zisheng Pills in the Treatment of Malignant Tumor Targeted Drug-Related Diarrhea with Spleen and Stomach Weakness Syndrome. Chin J Tradit Chin Med, 64(19): 1988–1994.
Liu H, Jie Y, Han X, 2021, Application Effect of Radioactive Seed Implantation Combined with Anti-Angiogenesis Targeted Therapy in Patients with Oral and Maxillofacial Malignant Tumors. Henan Med Res, 31(9): 1587–1591.
Wang J, Shen Y, Lai M, et al., 2023, Clinical Study of Modified Shengyang Sanhuo Decoction Combined with Vitamin B2 in the Treatment of Oral Ulcer Caused by Malignant Tumor Targeted Drugs. New Tradit Chin Med, 55(21): 1–7.
Zhang JC, Sun XM, Yu Y, et al., 2023, The Effect of Traditional Chinese Medicine with the Same Origin of Medicine and Food on Colorectal Cancer Patients During Chemotherapy. Chin J Exp Pharm, 29(19): 228–234.
Xu YJ, Liu MH, Chen JJ, et al., 2024, Research Progress on the Mechanism of Sorafenib Resistance Mediated by IL-6/STAT3 Signaling Pathway in Hepatocellular Carcinoma. Mod Med Hyg, 40(17): 3017–3022.
Yi X, 2023, Clinical Efficacy of Targeted Drug Therapy Combined with Chemotherapy in the Treatment of Malignant Tumors. Chin Med, 8(10): 71–73.
Wang Y, Liu B, 2024, Opportunities and Challenges of Mesothelial Targeted Drugs in Tumor Immunotherapy. Chin J Cancer Biother, 31(9): 841–848.
Xiao T, Liu J, Gao L, 2023, Treatment of Acute T Lymphoblastic Leukemia with Targeted Drugs Combined with Allogeneic Hematopoietic Stem Cell Transplantation. J Clin Med, 40(10): 654–658.
Jia Z, Wang L, Liu Z, et al., 2021, Mechanism and Targeting Strategy of Gemcitabine Resistance in Pancreatic Cancer Tumor Microenvironment. Chin J Biochem Mol Biol, 40(9): 1215–1221.
Share
Back to top
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept